|Other Names||DNA (cytosine-5)-methyltransferase 3-like, DNMT3L|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1040a was selected from the C-term region of human Dnmt3L. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Catalytically inactive regulatory factor of DNA methyltransferases. It is essential for the function of DNMT3A and DNMT3B. Activates DNMT3A and DNMT3B by binding to their catalytic domain. Accelerates the binding of DNA and AdoMet to the methyltransferases and dissociates from the complex after DNA binding to the methyltransferases. Recognizes unmethylated histone H3 lysine 4 (H3K4) and induces de novo DNA methylation by recruitment or activation of DNMT3.|
|Tissue Location||Expressed at low levels in several tissues including testis, ovary, and thymus|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CpG methylation is an epigenetic modification that is important for embryonic development, imprinting, and X-chromosome inactivation. Studies in mice have demonstrated that DNA methylation is required for mammalian development. This gene encodes a nuclear protein with similarity to DNA methyltransferases. This protein is not thought to function as a DNA methyltransferase as it does not contain the amino acid residues necessary for methyltransferase activity. However, this protein does stimulate de novo methylation by DNA cytosine methyltransferase 3 alpha and it is thought to be required for the establishment of maternal genomic imprints. This protein also mediates transcriptional repression through interaction with histone deacetylase 1. Alternative splicing results in two transcript variants. An additional splice variant has been described but its biological validity has not been determined.
Chedin, F., et al., Proc. Natl. Acad. Sci. U.S.A. 99(26):16916-16921 (2002).Kierszenbaum, A.L., Mol. Reprod. Dev. 63(3):269-272 (2002).Deplus, R., et al., Nucleic Acids Res. 30(17):3831-3838 (2002).Hata, K., et al., Development 129(8):1983-1993 (2002).Burgers, W.A., et al., Trends Genet. 18(6):275-277 (2002).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.